Company Overview and News


Add BMYMP
to your dashboard

Headline News

AbbVie Stock: Performance in 3Q17

16h marketrealist
Headquartered in Illinois, AbbVie (ABBV) is one of the leading biopharmaceutical companies dealing with research-based pharmaceutical products. It develops and markets pharmaceutical drugs and therapies that address complex and serious diseases worldwide. The company was separated from Abbott Laboratories (ABT) in 2013. (136-0)

Allergan Stock: Performance in 3Q17

16h marketrealist
Headquartered in Dublin, Ireland, Allergan (AGN) is one of the leading pharmaceutical companies, dealing with both generic and specialty pharmaceutical products. The US administrative headquarters are in Parsippany, New Jersey. Allergan has segregated its business into three segments: US General Medicine, US Specialized Therapeutics, and the International business. (79-0)

Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

16h zacks
We expect GlaxoSmithKline plc (GSK - Free Report) to beat expectations when it reports third-quarter 2017 results on Oct 25, before the market opens. Last quarter, the company delivered a positive earnings surprise of 2.94%. (139-0)

CELG Stock: Catch This Falling Knife -- Go Long Celgene Corporation | InvestorPlace

23h investorplace
Last night, Celgene Corporation (NASDAQ:CELG) released a headline that they canceled phase three for their potential solution to Crohn’s disease. The stock is now trading down 10%. This means that it would now be down 16% since early October. (351-2)

Roche Earnings: In A Competitive Storm With Shaky Defenses - Bloomberg

2017-10-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (122-0)

Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)

2017-10-19 seekingalpha
US Treasury Secretary Steven Mnuchin said that the tax reform is baked into the market and if it doesn't go through, it will impact stocks negatively. Cramer thinks otherwise. "Look, I appreciate he's trying to get Congress motivated, but just on the facts, I think he's quite wrong. The truth is, most executives don't believe tax reform is coming. It's simply not integral to this market. Yes, they've lost faith," he said. (156-1)

Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

2017-10-18 zacks
We expect Biogen Inc. (BIIB - Free Report) , a well-known name in the multiple sclerosis (MS) market, to beat expectations when it reports third-quarter 2017 results on Oct 24, before the market opens. Last quarter, the company delivered a positive earnings surprise of 15.60%. (130-0)

Exploring AstraZeneca's Two-Prong Assault On Lung Cancer

2017-10-18 seekingalpha
AstraZeneca has made huge moves in the 2nd half of 2017, particularly with respect to lung cancer therapy (145-0)

3 Things In Biotech You Should Learn Today: October 18, 2017

2017-10-18 seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. (104-0)

Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?

2017-10-18 zacks
Eli Lilly and Company (LLY - Free Report) will report third-quarter 2017 results on Oct 24, before the market opens. Last quarter, the company delivered a positive earnings surprise of 6.73%. (89-0)

Corporate News Blog - Inovio Initiates Phase-1b/2 Cancer Efficacy Trial

2017-10-18 accesswire
LONDON, UK / ACCESSWIRE / October 18, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Inovio Pharmaceuticals, Inc. (NASDAQ: INO), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=INO. The Plymouth Meeting , Pennsylvania based clinical-stage pharmaceutical Company announced on October 16, 2017, that it has commenced a phase-1b/2 immuno-oncology trial to evaluate Genentech/Roche's atezolizumab (TECENTRIQ®) in combination with Inovio's INO-5401and INO-9012 for the treatment of advanced bladder cancer. (92-0)

US Pharma Mergers and Acquisitions in 3Q17

2017-10-18 marketrealist
The US pharmaceutical sector consists of different setups pertaining to development, manufacturing or production, and drug marketing. These setups consist of drug manufacturers, drug marketers, and biotechnology companies. (79-0)

Missouri appeals court tosses $72M US award in talcum powder case

2017-10-18 cbc.ca
A Missouri appeals court on Tuesday that vacated a $72 million US award to an Alabama woman who claimed her use of Johnson & Johnson products that contained talcum contributed to her ovarian cancer has thrown the fate of awards in similar cases into doubt. (72-0)

Alexandria Real Estate Equities: Buy Below $110 Per Share

2017-10-17 seekingalpha
Major patent cliffs from 2012-2016 depressed revenues of key tenants. This trend will moderate in the coming years. (113-0)

Appeals court throws out $72-million award in talc powder case due to jurisdictional issue

2017-10-17 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com (72-0)

UPDATE 1-J&J wins reversal of $72 mln verdict over talc cancer risks

2017-10-17 reuters
(Reuters) - Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company’s talc-based products like Johnson’s Baby Powder. (73-0)

Bristol-Myers Gets Priority Review for Opdivo Label Expansion

2017-10-17 zacks
Bristol-Myers Squibb Company (BMY - Free Report) announced that that the FDA has granted priority review to the supplemental Biologics License Application (sBLA) for the label expansion of Opdivo. (113-0)

FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx

2017-10-17 zacks
Exelixis, Inc. (EXEL - Free Report) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for Cabomteyx. The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma (RCC). The FDA determined the sNDA to be sufficiently complete. (106-0)

Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

2017-10-17 marketwired
NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors. (152-0)

Biotech Analysis Central: Daily Pharma News - October 17, 2017

2017-10-17 seekingalpha
Bristol-Myers Squibb achieves encouraging data in small cell lung cancer patients with both Opdivo alone and in combination with Yervoy (108-0)

Merck's Risk/Reward Is Compelling

2017-10-16 seekingalpha
DCF analysis reveals upside potential of around 16% based on a perpetuity growth method or 15% based on an EBITDA exit multiple method. (113-0)

Merck Pulls The Plug On Cholesterol Drug

2017-10-16 seekingalpha
Phase 3 data was lackluster at best, which was a wise decision for Merck to not file for its CETP inhibitor Anacetrapib to the FDA. (75-0)

Top Analyst Upgrades and Downgrades: Adobe, Apple, Bristol-Myers, Citigroup, Ford, Groupon, Phillips 66, United Rentals and More

2017-10-16 247wallst
Stocks were indicated to open higher on Monday, and investors understand that the Dow, S&P and Nasdaq are all fighting for all-time highs again. The trend that has ruled without fail for more than five years of this eight-and-a-half-year-old bull market is that investors keep finding new reasons to buy stocks after every market sell-off. Investors are also hunting for new investing and trading ideas with their capital. (395-1)

Sirona Biochem to Present Kel-01 at Cosmetic 360 in Paris, France

2017-10-16 marketwired
VANCOUVER, BC--(Marketwired - October 16, 2017) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company") announced that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will attend and present on the trade floor at Cosmetic 360 in Paris, France on October 18-19, 2017. Cosmetic 360 is an international event that brings together the leading advancements in science with the largest, most influential cosmetics companies. (236-1)

Corporate News Blog - Bristol-Myers Squibb's Opdivo to be Available for Head and Neck Cancer Patients in UK

2017-10-16 accesswire
LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Bristol-Myers Squibb Co. (NYSE: BMY), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=BMY. The Company announced on October 13, 2017, that the UK's National Institute of Health and Care Excellence (NICE), the advisor to the National Health Service (NHS) for cost and quality, has allowed Bristol-Myers Squibb's Opdivo (nivolumab) to be available for metastatic head and neck cancer patients who have not responded to chemo with six months and the cancer has spread to other parts of the body. (87-0)

CUSIP: 110122908